Literature DB >> 32970049

A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors.

Kohei Tsuji1, David Hymel, Terrence R Burke.   

Abstract

Using a probe consisting of a fluorescein-labeled variant of the potent polo-like kinase 1 (Plk1) inhibitor BI2536 [FITC-PEG-Lys(BI2536) 4], we were able to determine half maximal inhibitory concentration (IC50) of ATP-competitive Type 1 inhibitors of Plk1 by means of a fluorescence recovery assay. This methodology represents a cost-effective and simple alternative to traditional kinase assays for initial screening of potential Plk1 inhibitors.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32970049      PMCID： PMC7523589          DOI： 10.1039/d0ay01223h

Source DB:  PubMed          Journal:  Anal Methods        ISSN： 1759-9660            Impact factor:   2.896


  25 in total

1.  Fluorescence Polarization (FP) Assays for Monitoring Peptide-Protein or Nucleic Acid-Protein Binding.

Authors:  Nathan J Moerke
Journal:  Curr Protoc Chem Biol       Date:  2009-12-01

2.  The challenge of selecting protein kinase assays for lead discovery optimization.

Authors:  Haiching Ma; Sean Deacon; Kurumi Horiuchi
Journal:  Expert Opin Drug Discov       Date:  2008-06       Impact factor: 6.098

3.  Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.

Authors:  Sarah Keppner; Ewgenij Proschak; Gisbert Schneider; Birgit Spänkuch
Journal:  ChemMedChem       Date:  2009-11       Impact factor: 3.466

Review 4.  Understanding the Polo Kinase machine.

Authors:  V Archambault; G Lépine; D Kachaner
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

5.  Bioorthogonal probes for polo-like kinase 1 imaging and quantification.

Authors:  Ghyslain Budin; Katherine S Yang; Thomas Reiner; Ralph Weissleder
Journal:  Angew Chem Int Ed Engl       Date:  2011-08-24       Impact factor: 15.336

6.  Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase.

Authors:  Yongsheng Liu; Kevin R Shreder; Wenzhi Gai; Sergio Corral; Douglas K Ferris; Jonathan S Rosenblum
Journal:  Chem Biol       Date:  2005-01

7.  BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Authors:  Dorothea Rudolph; Martin Steegmaier; Matthias Hoffmann; Matthias Grauert; Anke Baum; Jens Quant; Christian Haslinger; Pilar Garin-Chesa; Günther R Adolf
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

Review 8.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

Authors:  Brian D Cholewa; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Res       Date:  2013-11-21       Impact factor: 12.701

9.  A fluorescence lifetime based binding assay to characterize kinase inhibitors.

Authors:  Connie S Lebakken; Kurt W Vogel
Journal:  J Biomol Screen       Date:  2007-07-20

10.  Staurosporine-based binding assay for testing the affinity of compounds to protein kinases.

Authors:  Ganesh H Iyer; Paul Taslimi; S Pazhanisamy
Journal:  Anal Biochem       Date:  2007-11-09       Impact factor: 3.365
View more
  1 in total

1.  Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1.

Authors:  Kohei Tsuji; David Hymel; Buyong Ma; Hirokazu Tamamura; Ruth Nussinov; Terrence R Burke
Journal:  RSC Chem Biol       Date:  2022-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.